The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models. Microbiotica's platform focuses on microbiome science to identify gut bacteria linked to phenotype with unprecedented precision, and it has a world leading microbiome Culture Collection, proprietary Reference Genome Database, and advanced microbiome bioinformatics. Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype.